Covaxin

Covaxin News

Completing fight against COVID in India: Why adults should not ignore precautionary dose
Health

Completing fight against COVID in India: Why adults should not ignore precautionary dose

The mortality rate because of COVID has come down but, we should not go away from taking the necessary precautions

Biological E Limited delivers 10 crore doses of Corbevax to Centre
Health

Biological E Limited delivers 10 crore doses of Corbevax to Centre

Corbevax is expected to be available as a booster dose on the CoWIN App in public and private vaccination centres from 12 August

COVID-19: Corbevax approved as precaution dose for adults vaccinated with Covaxin, Covishield
India

COVID-19: Corbevax approved as precaution dose for adults vaccinated with Covaxin, Covishield

This is for the first time that a booster dose that is different from the one used for primary vaccination against Covid has been allowed in the country

Centre to soon approve Biological E's Corbevax as precaution dose for people above 18 years
Health

Centre to soon approve Biological E's Corbevax as precaution dose for people above 18 years

If approved by the government, this would be the first time a booster dose of a COVID vaccine different from the one used for primary vaccination would be allowed in the country

Linking COVID-19 vaccine with Monkeypox: Busting the myths
Health

Linking COVID-19 vaccine with Monkeypox: Busting the myths

The virus has been named Monkeypox because initially it was detected in a monkey

India supplied 23.9 crore COVID-19 vaccine doses to 101 countries, UN entities: Centre
India

India supplied 23.9 crore COVID-19 vaccine doses to 101 countries, UN entities: Centre

Minister of State for Health Bharati Pravin Pawar said as on 19 July, 2022, a total of 200.34 crore COVID-19 vaccine doses have been administered to beneficiaries above 12 years of age in the country

200 crore vaccinations: How India under Narendra Modi scripted Covid success story
India

200 crore vaccinations: How India under Narendra Modi scripted Covid success story

The country crossed a record 200 crore Covid-19 vaccinations on 17 July 2022 within barely 18 months of launching this exercise on 16 January last year

Over 57% seniors faced mental health issues during COVID-19, 59% say government managed pandemic well
India

Over 57% seniors faced mental health issues during COVID-19, 59% say government managed pandemic well

The fear of COVID-19 infection was the most prevalent factor that contributed to the rising mental health concerns among seniors

Vaxxed to the max: A look at India's COVID vaccination drive that is set to overtake US, Europe and Canada combined
India

Vaxxed to the max: A look at India's COVID vaccination drive that is set to overtake US, Europe and Canada combined

As per official data, a total of 1,96,24,21,213 doses have been administered so far across the country, which is set to cross the combined doses of the United States, Europe and Canada

Covaxin safe, well-tolerated in 2-18 years age-group, announces Bharat Biotech
Health

Covaxin safe, well-tolerated in 2-18 years age-group, announces Bharat Biotech

The clinical trial conducted in the paediatric population between June 2021 to September 2021 has shown safety, less reactogenic, and robust immunogenicity

As COVID-19 cases rise, vaccines play vital role to prevent mass hospitalization, adverse outcomes
Health

As COVID-19 cases rise, vaccines play vital role to prevent mass hospitalization, adverse outcomes

Vaccines play a crucial role in preventing infection, hospitalizations, and adverse outcomes which cause deaths

Germany to recognise Bharat Biotech's COVID-19 vaccine Covaxin for travel from 1 June
India

Germany to recognise Bharat Biotech's COVID-19 vaccine Covaxin for travel from 1 June

In November last year, the World Health Organisation recommended Emergency Use Listing (EUL) status for Covaxin

In 15-18 years age group, over 80% got first dose of COVID vaccine, says Mandaviya
Health

In 15-18 years age group, over 80% got first dose of COVID vaccine, says Mandaviya

India began inoculating those in the age group of 15-18 years from 3 January and so far 5.92 crore beneficiaries in this age group have been given the first dose

COVID-19 is not over yet and why vaccination is important for better fighting chance
Health

COVID-19 is not over yet and why vaccination is important for better fighting chance

Vaccination is a worldwide accepted strategy to encounter the COVID-19 as soon as possible with the vaccines approved by their public health authorities

COVID-19: Bharat Biotech seeks DCGI's permission to conduct Covaxin booster trials in 2-18 age group
India

COVID-19: Bharat Biotech seeks DCGI's permission to conduct Covaxin booster trials in 2-18 age group

The company has already conducted trials in the age group of 2-18 for two doses of Covaxin

Bharat Biotech must address WHO's Covaxin supply suspension to avoid EUL cancellation: MEA
Health

Bharat Biotech must address WHO's Covaxin supply suspension to avoid EUL cancellation: MEA

Following an inspection of the Bharat Biotech premises on 14 March for Covaxin's EUL, WHO announced the suspension of the vaccine's supply owing to deficiencies in good manufacturing practices

Corbevax, Biological E's COVID-19 vaccine, gets DCGI's emergency use authorisation for children aged 5-12
India

Corbevax, Biological E's COVID-19 vaccine, gets DCGI's emergency use authorisation for children aged 5-12

The DCGI has also given restricted emergency use authorisation to Covaxin, manufactured by Hyderabad based pharmaceutical company - Bharat Biotech, for children between 6 and 12 years

DCGI clears Bharat Biotech's Covaxin for restricted emergency use in children aged 6-12 years
India

DCGI clears Bharat Biotech's Covaxin for restricted emergency use in children aged 6-12 years

Bharat Biotech has been asked to submit safety data alongwith the data on adverse event with due analysis, every 15 days for the first two months and after that monthly data for up to five months

Adar Poonawalla warns against return to business-as-usual approach
Business

Adar Poonawalla warns against return to business-as-usual approach

He pointed out that there is rising vaccine fatigue among the public as the main reason for the low off-take of the vaccines even after the firm has massively slashed the price from Rs 600 to Rs 225 a dose

DCGI expert panel holds meet on recommendations to use Corbevax, Covaxin vaccines for 5-12 age group
Health

DCGI expert panel holds meet on recommendations to use Corbevax, Covaxin vaccines for 5-12 age group

India is currently administering two COVID-19 vaccines for children above 12